Literature DB >> 3998114

Selective reactivity of antibodies to human immunoglobulins G, M, and A with rubella virus proteins.

P Partanen, H Seppänen, J Suni, A Vaheri.   

Abstract

Proteins of purified rubella virus were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to nitrocellulose, and immunoblotted with human sera and immunoglobulin class heavy-chain-specific peroxidase conjugates. The levels of rubella antibodies in these sera were predetermined by the radial hemolysis test, the density gradient centrifugation method for immunoglobulin M (IgM) antibodies, and IgG-, IgM-, and IgA-specific enzyme immunoassays. In immunoblotting, rubella-specific IgG antibodies reacted with both envelope glycoproteins (E1 and E2) and the capsid protein (C). In contrast, rubella IgM antibodies reacted predominantly with E1, whereas the specific reactivity of IgA antibodies was directed mainly to the capsid protein. Purified IgM rheumatoid factor added to IgG-positive, IgM-negative serum did not give false-positive reactivity in the immunoblotting test as it did in solid-phase enzyme immunoassays. The immunoglobulin class-specific reactivities with the different viral proteins are expected to have diagnostic applications.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3998114      PMCID: PMC271785          DOI: 10.1128/jcm.21.5.800-802.1985

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

2.  Rubella: a method for rapid diagnosis of a recent infection by demonstration of the IgM antibodies.

Authors:  T Vesikari; A Vaheri
Journal:  Br Med J       Date:  1968-01-27

3.  Antibody response in serum and nasopharynx after naturally acquired and vaccine-induced infection with rubella virus.

Authors:  P L Ogra; D Kerr-Grant; G Umana; J Dzierba; D Weintraub
Journal:  N Engl J Med       Date:  1971-12-09       Impact factor: 91.245

4.  Structural proteins and subunits of rubella virus.

Authors:  A Vaheri; T Hovi
Journal:  J Virol       Date:  1972-01       Impact factor: 5.103

5.  Radioimmunoassay for antibodies to rubella virus and its ribonucleoprotein component.

Authors:  L Ho-Terry; A Cohen
Journal:  J Med Microbiol       Date:  1979-11       Impact factor: 2.472

6.  Immunochemical identification of rubella virus hemagglutinin.

Authors:  M N Waxham; J S Wolinsky
Journal:  Virology       Date:  1983-04-15       Impact factor: 3.616

7.  Degradation of rubella virus envelope components.

Authors:  L Ho-Terry; A Cohen
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

8.  Hemolysis-in-gel test in immunity surveys and diagnosis of rubella.

Authors:  P Väänänen; A Vaheri
Journal:  J Med Virol       Date:  1979       Impact factor: 2.327

9.  Immunoblot analysis of Toxoplasma gondii antigens by human immunoglobulins G, M, and A antibodies at different stages of infection.

Authors:  P Partanen; H J Turunen; R T Paasivuo; P O Leinikki
Journal:  J Clin Microbiol       Date:  1984-07       Impact factor: 5.948

10.  Evaluation of solid-phase enzyme-immunoassay procedure in immunity surveys and diagnosis of rubella.

Authors:  A Vaheri; E M Salonen
Journal:  J Med Virol       Date:  1980       Impact factor: 2.327

View more
  11 in total

1.  Detection of rubella virus-specific immunoglobulin G (IgG), IgM, and IgA antibodies by immunoblot assays.

Authors:  T Zhang; C A Mauracher; L A Mitchell; A J Tingle
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

2.  Differences in antibody responses with rapid agglutination tests for the detection of rubella antibodies.

Authors:  M A Chernesky; D J DeLong; J B Mahony; S Castriciano
Journal:  J Clin Microbiol       Date:  1986-04       Impact factor: 5.948

3.  Immunoglobulin A antibodies to Trypanosoma cruzi antigens in digestive forms of Chagas' disease.

Authors:  K S Primavera; S Hoshino-Shimizu; E S Umezawa; B A Peres; D A Manigot; M E Camargo
Journal:  J Clin Microbiol       Date:  1988-10       Impact factor: 5.948

4.  Screening test for rheumatic diseases: a combined enzyme immunoassay of rheumatoid factors and antibodies to DNA and extractable nuclear antigens.

Authors:  P Kurki; M Gripenberg; P Partanen; T Helve
Journal:  J Clin Pathol       Date:  1987-12       Impact factor: 3.411

5.  Development of a highly specific and sensitive rubella immunoglobulin M antibody capture enzyme immunoassay that uses enzyme-labeled antigen.

Authors:  H Seppänen
Journal:  J Clin Microbiol       Date:  1990-04       Impact factor: 5.948

6.  Sequential serological studies of homosexual men with and without HIV infection. Epstein-Barr virus activation preceding and following HIV seroconversion.

Authors:  A Schattner; N Hanuka; B Sarov; I Sarov; Z Handzel; Z Bentwich
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

7.  An enzyme immunoassay for immunoglobulin M antibodies to Toxoplasma gondii which is not affected by rheumatoid factor or immunoglobulin G antibodies.

Authors:  T M Lin; M W Chin-See; S P Halbert; J M Joseph
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

8.  Diagnostic potential of baculovirus-expressed rubella virus envelope proteins.

Authors:  H Seppänen; M L Huhtala; A Vaheri; M D Summers; C Oker-Blom
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

9.  Performance of two new enzyme immunoassays for the detection of IgM and IgG antibodies to rubella.

Authors:  C Granberg; O Meurman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-06       Impact factor: 3.267

10.  Investigation of human immune response to Micropolyspora faeni antigens by enzyme-linked immunoelectrodiffusion assay and immunoblotting.

Authors:  C Aznar; P M Andre; J Deunff; R Robert
Journal:  J Clin Microbiol       Date:  1988-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.